Table 3. Correlation of E2Fs’ genes expression with OS in GC patients with different treatment strategies.

E2Fs	Treatment	Cases	HR (95% CI)	P-value
E2F1	Surgery alone	380	1.45 (1.06−1.97)	0.019*
	5FU-based adjuvant	153	2.06 (1.36−3.13)	0.00054*
	Other adjuvant	76	0.56 (0.23−1.37)	0.2
E2F2	Surgery alone	380	0.59 (0.42−0.83)	0.0022*
	5FU-based adjuvant	34	2.47 (0.94−6.44)	0.058
	Other adjuvant	76	0.4 (0.16−0.99)	0.041*
E2F3	Surgery alone	380	1.43 (1.05−1.95)	0.023*
	5FU-based adjuvant	153	1.8 (1.24−2.62)	0.0018*
	Other adjuvant	76	0.44 (0.18−1.08)	0.064
E2F4	Surgery alone	380	1.41 (1.02−1.93)	0.034*
	5FU-based adjuvant	153	1.81 (1.22−2.68)	0.0026*
	Other adjuvant	76	0.26 (0.1−0.73)	0.0056*
E2F5	Surgery alone	380	0.76 (0.56−1.04)	0.085
	5FU-based adjuvant	153	1.85 (1.27−2.7)	0.0013*
	Other adjuvant	76	0.26 (0.1−0.67)	0.0028*
E2F6	Surgery alone	380	0.85 (0.62−1.17)	0.31
	5FU-based adjuvant	153	1.78 (1.24−2.55)	0.0015*
	Other adjuvant	76	3.33 (0.77−14.37)	0.087
E2F7	Surgery alone	380	0.64 (0.47−0.86)	0.0033*
	5FU-based adjuvant	34	3.24 (1.26−8.28)	0.01*
	Other adjuvant	76	0.51 (0.2−1.27)	0.14

^*P<0.05.